tbuckley/cabot-search huggingface dataset:
Off-label and compendia use of chemotherapy in patients with metastatic cancer.
Authors: Dawn L. Hershman, Alfred I. Neugut, Donna Buono, Catherine A. Richards, Sherry A. Glied, Jason Dennis Wright
Journal: Journal of Clinical Oncology (2013)

6509 Background: In 2012, ASCO Identified opportunities to improve the quality and value of cancer care by reducing inappropriate and/or prolonged use of chemotherapy The NCCN compendium is recognized as an authoritative reference for insurance coverage for drug indications without FDA approval. We evaluated FDA-approved, compendia and unapproved use of chemotherapy. Methods: We useddata from the SEER-Medicare database to identify patients with metastatic cancer who received chemotherapy. For each tumor, drugs with &gt;3 claims were identified. Each drug was classified as having an FDA-approved indication, an indication based on NCCN compendia guidelines or neither of these. The number of claims for each drug was calculated. Logistic regression was used to assess the factors that Results: Between 1998-2007, 37,351 subjects were identified as having received chemotherapy; of these, 24,876 (66.6%) received only FDA approved drugs, and 12,475 (33.4%) received at least one unapproved drug. Of those who received an unapproved drug, 8,669 (69%) received a drug with a compendia listing. Therefore, of the total population, 10% received a drug that was neither FDA nor compendia approved. The mean number of unapproved claims was 10.3 (SD=15.2) and the mean number of drugs was 1.3. Unapproved use was highest in subjects with prostate and lowest in patients with colon cancer. In a multivariate analysis, unapproved use decreased with increasing age and &gt;2 comorbid conditions. Compared to prostate cancer, the odds of having an unapproved drug was lower for breast (OR=0.27), colon (OR=0.08), lung (OR=0.65), ovary (OR=0.38), uterus (OR=0.49) and myeloma (OR=0.60). No patients with colon or prostate cancer received compendia-approved drugs. Over 90% of unapproved use for breast, ovary and lung cancer were compendia-approved. Costs associated with unapproved/compendia use will be presented. Conclusions: A large fraction of patients who use chemotherapy receive FDA-unapproved drugs; however, the majority of those drugs are acknowledged by NCCN. A better understanding of the costs and benefits of compendia-approved drugs is warranted to reduce the costs of cancer care.
Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies
Authors: Marzia Capelletti, Jessica Liegel, Maria Themeli, Tuna Mutis, Dina Stroopinsky, Shira Orr, Daniela Torres, Adam Morin, Gertrude Gunset, Haider Ghiasuddin, Maryam Rahimian, Myrna Nahas, Lina Bisharat, Shufen Meng, Nikhil C. Munshi, Donald Kufe, Jacalyn Rosenblatt, Michel Sadelain, David E. Avigan
Journal: Blood (2019)
Endoscopic mucosal resection is effective for laterally spreading lesions at the anorectal junction
Authors: Neal Shahidi, Mayenaaz Sidhu, Sergei Vosko, W Arnout van Hattem, Iddo Bar-Yishay, Scott Schoeman, David J Tate, Bronte Holt, Luke F Hourigan, Eric Yt Lee, Nicholas G Burgess, Michael J Bourke
Journal: Gut (2019)

Objective The optimal approach for removing large laterally spreading lesions at the anorectal junction (ARJ-LSLs) is unknown. Endoscopic mucosal resection (EMR) is a definitive therapy for colorectal LSLs. It is unclear whether it is an effective modality for ARJ-LSLs. Design EMR outcomes for ARJ-LSLs (distal margin of ≤20 mm from the dentate line) in comparison with rectal LSLs (distal margin of &gt;20 mm from the dentate line) were evaluated within a multicentre observational cohort of LSLs of ≥20 mm. Technical success was defined as the removal of all polypoid tissue during index EMR. Safety was evaluated by the frequencies of intraprocedural bleeding, delayed bleeding, deep mural injury (DMI) and delayed perforation. Long-term efficacy was evaluated by the absence of recurrence (either endoscopic or histologic) at surveillance colonoscopy (SC). Results Between July 2008 and August 2019, 100 ARJ-LSLs and 313 rectal LSLs underwent EMR. ARJ-LSL median size was 40 mm (IQR 35–60 mm). Median follow-up at SC4 was 54 months (IQR 33–83 months). Technical success was 98%. Cancer was present in three (3%). Recurrence occurred in 15.4%, 6.8%, 3.7% and 0% at SC1–SC4, respectively. Among 30 ARJ-LSLs that received margin thermal ablation, no recurrence was identified at SC1 (0.0% vs 25.0%, p=0.002). Technical success, recurrence and adverse events were not different between groups, except for DMI (ARJ-LSLs 0% vs rectal LSLs 4.5%, p=0.027). Conclusion EMR is an effective technique for ARJ-LSLs and should be considered a first-line resection modality for the majority of these lesions.
Treatment of Varicose Veins
Authors: F. D. Hindmarsh
Journal: BMJ (1947)

health.The splint was applied over the head, neck, and back and at the same time the patient was forbidden to speak.In tfhree days the temperature was normal and the swollen glands disappeared.To-day sulphonamides or penicillin may be em- ployed.At any rate fixation of the head and neck by means of a splint is an excellent treatment of inflammations in the neck region as well as injuries of the hypopharynx and upper parts of the oesophagus.-Iam, etc., Wroclaw, Poland.STANISLAW TUSZEWSKI.
A population-based case-control study of glutathione peroxidase 1 (GPX1) gene polymorphisms and risk of breast cancer
Authors: Qiuyin Cai, Qi Dai, Xiao-Ou Shu, Jia-Rong Cheng, Regina Courtney, Wanqing Wen, Jeffrey R. Smith, Yu-Tang Gao, Wei Zheng
Journal: Cancer Research (2005)

4917  It has been suggested that oxidative stress play an important role in breast cancer carcinogenesis. Glutathione peroxidase 1 (GPX1) is involved in the detoxification of hydrogen peroxide, and is one of the most important antioxidant enzymes in humans. Several putative function polymorphisms of the GPX1 gene have been reported. Among them, Pro198Leu, Ala repeat polymorphisms in the coding region and +2C/T polymorphism in the non-coding region are known to decrease GPX1 enzyme activity and transcriptional activity. We evaluated these three functional polymorphisms in association with breast cancer risk using data from the Shanghai Breast Cancer Study, a population-based case-control study conducted in urban Shanghai during 1996 to 1998. Included in this study were 1134 cases and 1230 age-matched community controls who had completed the in-person interview and donated a blood sample to the study. Pro198Leu, Ala repeat, and +2C/T polymorphisms are in strong linkage disequilibrium. The minor allele frequencies of these polymorphisms among controls are low, with Ala5 = 0.075, Ala6 = 0.005, 198Leu = 0.065, and +2T = 0.073. None of the polymorphisms showed a statistically significant association with breast cancer risk. TT genotype of +2C/T polymorphisms was associated with a non-significantly increased breast cancer risk (OR=1.6, 95% CI=0.7-3.4). Analysis combining three polymorphisms did not reveal a significant association with breast cancer risk. No apparent interaction between these polymorphisms and antioxidant intake was found. Results of this study suggest that the three GPX1 gene polymorphisms understudy do not play a major role in the etiology of breast cancer among Chinese women.
The Clinical and Functional Relevance of the Transforming AKT E17K Mutation in T-ALL
Authors: Jordy C.G. Van Der Zwet, Jessica G.C.A.M. Buijs-Gladdines, Izabela Mollova, Laura Graus, Frank L. Bos, Anne C. Rios, Jules P.P. Meijerink
Journal: Blood (2019)
Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study
Authors: Jean-Pierre Issa, Marco Gobbi, Patricia L. Kropf, Pierre Fenaux, Gail J. Roboz, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop M. Kantarjian, Jan Novak, Wieslaw W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph M Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A. Griffiths, Karen W.L. Yee, Yong Hao, Mohammad Azab, Hartmut Döhner
Journal: Blood (2019)
Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma
Authors: Ada Dona', Domenico Viola, Enrico Caserta, Francesca Besi, James F Sanchez, Guido Marcucci, Jonathan J Keats, Amrita Y. Krishnan, Matt Coffey, Douglas W. Sborov, Gerard Nuovo, Craig C Hofmeister, Flavia Pichiorri
Journal: Blood (2019)
New Therapies for Emerging Endotypes of Asthma
Authors: Geoffrey Lowell Chupp, Ravdeep Kaur, Anne Mainardi
Journal: Annual Review of Medicine (2019)

The presentation, pathobiology, and prognosis of asthma are highly heterogeneous and challenging for clinicians to diagnose and treat. In addition to the adaptive immune response that underlies allergic inflammation, innate immune mechanisms are increasingly recognized to be critical mediators of the eosinophilic airway inflammation present in most patients with asthma. Efforts to classify patients by severity and immune response have identified a number of different clinical and immune phenotypes, indicating that the innate and adaptive immune responses are differentially active among patients with the disease. Advances in the detection of these subgroups using clinical characteristics and biomarkers have led to the successful development of targeted biologics. This has moved us to a more personalized approach to managing asthma. Here we review the emerging endotypes of asthma and the biologics that have been developed to treat them.
BALB/c-hCD3E Transgenic Mice: An Ideal Animal Model for In Vivo Efficacy Study of CD3-Bispecific Antibodies
Authors: Cunxiang Ju, Mingkun Zhang, Dongjing Jia, Jing Tang, Shuai Li, Jing Zhao, Demin Wang, Xiang Gao
Journal: Blood (2019)
Prognostic Factors for Survival after Allogeneic Transplantation in Acute Lymphoblastic Leukemia
Authors: Christine Greil, Monika Engelhardt, Gabriele Ihorst, Hartmut Bertz, Reinhard Marks, Robert Zeiser, Justus Duyster, Jürgen Finke, Ralph Wäsch
Journal: Blood (2019)
Imaging Phenotypes of Breast Cancer Heterogeneity in Preoperative Breast Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Scans Predict 10-Year Recurrence
Authors: Rhea D. Chitalia, Jennifer Rowland, Elizabeth S. McDonald, Lauren Pantalone, Eric A. Cohen, Aimilia Gastounioti, Michael Feldman, Mitchell Schnall, Emily Conant, Despina Kontos
Journal: Clinical Cancer Research (2019)

Identifying imaging phenotypes and understanding their relationship with prognostic markers and patient outcomes can allow for a noninvasive assessment of cancer. The purpose of this study was to identify and validate intrinsic imaging phenotypes of breast cancer heterogeneity in preoperative breast dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) scans and evaluate their prognostic performance in predicting 10 years recurrence.Pretreatment DCE-MRI scans of 95 women with primary invasive breast cancer with at least 10 years of follow-up from a clinical trial at our institution (2002-2006) were retrospectively analyzed. For each woman, a signal enhancement ratio (SER) map was generated for the entire segmented primary lesion volume from which 60 radiomic features of texture and morphology were extracted. Intrinsic phenotypes of tumor heterogeneity were identified via unsupervised hierarchical clustering of the extracted features. An independent sample of 163 women diagnosed with primary invasive breast cancer (2002-2006), publicly available via The Cancer Imaging Archive, was used to validate phenotype reproducibility.Three significant phenotypes of low, medium, and high heterogeneity were identified in the discovery cohort and reproduced in the validation cohort (P < 0.01). Kaplan-Meier curves showed statistically significant differences (P < 0.05) in recurrence-free survival (RFS) across phenotypes. Radiomic phenotypes demonstrated added prognostic value (c = 0.73) predicting RFS.Intrinsic imaging phenotypes of breast cancer tumor heterogeneity at primary diagnosis can predict 10-year recurrence. The independent and additional prognostic value of imaging heterogeneity phenotypes suggests that radiomic phenotypes can provide a noninvasive characterization of tumor heterogeneity to augment personalized prognosis and treatment.
Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis
Authors: Surbhi Sidana, Surendra Dasari, Taxiarchis Kourelis, Angela Dispenzieri, David L Murray, Rebecca L. King, Ellen D. McPhail, Marina Ramirez-Alvarado, Shaji K. Kumar, Morie A. Gertz
Journal: Blood (2019)
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors
Authors: Giovanni Caocci, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa
Journal: Blood (2019)
원저 / 간성 뇌증의 치료로서 Rifaximin ( Normix ) 단기간 투여의 효능과 안전성
Authors: 김명환(Myoung Hwan Kim), 한광협(Kwang Hyub Han), 이관식(Kwan Sik Lee), 백용한(Yong Han Paik), 송건훈(Kun Hoon Song), 나호균(Ho Kyun Na), 문병수(Byung Soo Moon), 윤석화(Suk Hwa Yoon), 전재윤(Chae Yoon Chon), 문영명(Young Myoung Moon), 박인서(In Suh Park)
Journal: Clinical and Molecular Hepatology (2001)

Background/Aims: A prospective, randomized study was performed to evaluate the efficacy and safety of the short-term administration of rifaximin in the treatment of hepatic encephalopathy. Methods: Of the 64 patients diagnosed as having decompensated liver cirrhosis with hepatic encephalopathy, 39 patients were randomized to receive rifaximin and 25 patients to receive lactulose for seven days. Before and after the treatment we assessed changes in the level of serum ammonia, flapping tremor, patient's mental status, number connection test (NCT), and hepatic encephalopathy indices. Results: In rifaximin-treated group, the mean grade of serum ammonia (1.8→0.9), mental status (1.3→0.3), NCT (3.0→2.0), and flapping tremor (1.7→0.4) were improved after treatment. In the lactulose-treated group, the mean grade of serum ammonia (1.9→1.0), mental status (1.5→0.5), NCT (3.3→2.1), and flapping tremor (1.4→0.3) were improved after treatment. Side effects of abdominal pain (rifaximin group) and excessive diarrhea (lactulose group) were noted in 2 cases. The efficacy of treatment was not significantly different between rifaximin and lactulose-treated groups (84.3% vs. 95.3%). Conclusion: Rifaximin was as efficient and safe in the treatment of hepatic encephalopathy as lactulose in terms of efficacy. Rifaximin may be useful drug for the short-term treatment of hepatic encephalopathy.(Korean J Hepatol 2001;7:55-60)
Tako-tsubo cardiomyopathy following gastroscopy: a complication to consider
Authors: Martín Oricchio, Rodrigo Dorelo, Juan Pablo Bachini, Daniela Méndez, Adrián Canavesi
Journal: Endoscopy (2019)

A 69-year-old woman, who was a former smoker, presented with dysphagia to solids and liquids and epigastric pain over a period of 8 weeks. An upper gastrointestinal endoscopy was performed, without incident, and revealed gastric atrophy in the antrum ([Fig. 1]). Biopsies were taken according to the Sydney protocol.
Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates
Authors: Ehab L. Atallah, Islam Sadek, Xiting Cao, Dominick Latremouille-Viau, Irina Pivneva, Carmine Rossi, Annie Guerin, Vamsi Kota
Journal: Blood (2019)
Apolipoprotein AIF gene variant S347 is associated with increased risk of coronary heart disease and lower apolipoprotein AIV plasma concent rations
Authors: Wai-man R. Wong, Emma Hawe, Lai K. Li, George J. Miller, Viviane Nicaud, Len A. Pennacchio, Steve E. Humphries, Philippa J. Talmud
Journal: Circulation Research (2003)

Author(s): Wong, Wai-man R.; Hawe, Emma; Li, Lai K.; Miller, George J.; Nicaud, Viviane; Pennacchio, Len A.; Humphries, Steve E.; Talmud, Philippa J. | Abstract: The impact of common variants in the apolipoprotein gene cluster (APOC3-A4-A5) on prospective CHD risk was examined in healthy UK men. Of the 2808 men followed over nine years, 187 had a clinically defined CHD event. Examination of 9 single nucleotide polymorphisms (SNPs) in this group revealed that homozygotes for APOA4 S347 had significantly increased risk of CHD [Hazard ratio (HR) of 2.07 (95%CI 1.04-4.12)] while men homozygous for APOC3 1100T were protected (HR 0.28 (95%CI 0.09-0.87)). In stepwise multiple regression analysis, after entering all the variants and adjusting for established risk factors APOA4 T347S alone remained in the model. Using nine-SNP haplotype analysis, highest risk-estimate haplotypes carried APOA4 S347 and rare alleles of the two flanking intergenic markers. The protective effect of APOC31100T could be explained by negative linkage disequilibrium with these alleles. To determine the association of APOA4 T347S with apoAIVlevels, the relationship was examined in over 1600 healthy young European men and women. S347 homozygotes had significantly lower apoAIV plasma levels (13.48 + 0.6mg/dl) compared to carriers of the T347 allele (14.85 + 0.12 mg/dl) (p=0.025). These results demonstrate that genetic variation in and around APOA4, independent of effects of TG, is associated with risk of CHD and apoAIV levels, supporting an anti-atherogenic role for apoAIV.
Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies
Authors: Ryo Ishino, Yumi Kawase, Toshio Kitawaki, Naoshi Sugimoto, Maki Oku, Shumpei Uchida, Osamu Imataki, Akihito Matsuoka, Teruhisa Taoka, Kimihiro Kawakami, Tomoki Todo, Akifumi Takaori-Kondo, Norimitsu Kadowaki
Journal: Blood (2019)
Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosis
Authors: Tessa J. Barrett, Martin Schlegel, Felix Zhou, Mike Gorenchtein, Jennifer Bolstorff, Kathryn J. Moore, Edward A. Fisher, Jeffrey S. Berger
Journal: Science Translational Medicine (2019)

Platelet-induced myeloid Socs3 expression in humans and mice contributes to unresolved atherosclerosis inflammation and sustained plaque growth.
Erratum: SGLT2 inhibitors in combination therapy: From mechanisms to clinical considerations in type 2 diabetes management. (Diabetes Care (2018) 41 (1543–1556) DOI: 10.2337/dc18-0588)
Authors: Michaël J. B. van Baar, Charlotte C. van Ruiten, Marcel H. A. Muskiet, Liselotte van Bloemendaal, Richard G. IJzerman, Daniël H. van Raalte
Journal: Diabetes Care (2019)

In the article cited above, Fig. 3 was replaced. The data in the HbA1c (%) panel under 8.9 baseline was corrected. The online version of the article (https://doi.org/10.2337/dc18-0588) has been corrected.
Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project
Authors: Oliver Lomas, Sarah Gooding, Karthik Ramasamy, Angela Hamblin, Maite Cabes, Helene Marie-Pierre Dreau, Edward Wilson
Journal: Blood (2019)
Correlation of MRI derived parameters and SUV uptake obtained from FDG- PET-CT with human papillomavirus status in oropharyngeal squamous cell carcinomas
Authors: S. Goyal, V.P.B. Koyyala, A. Jajodia, A. Chaturvedi, M. Gairola, A. Rao, M. Sharma, S. Pasricha, P. Alhawat, V. Mahawar, B. Amrith, R. Tripathi
Journal: Annals of Oncology (2019)
EXTH-44. INHIBITION OF MerTK ACTIVATES GLIOBLASTOMA-ASSOCIATED MACROPHAGES AND INDUCES TUMOR CELL DEATH IN GLIOMA MICROENVIRONMENT
Authors: Yu-Ting Su, Madison Butler, Lee Hwang, Dragan Maric, Shelton Earp, Masaki Terabe, Mark Gilbert, Jing Wu
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Glioblastoma-associated macrophages and microglia (GAMs) are the predominant immune cells in the tumor microenvironment. Activation of MerTK, a receptor tyrosine kinase, triggers efferocytosis and polarizes GAMs to an immunosuppressive phenotype, promoting glioma growth. Our previous findings showed that UNC2371, a small-molecule inhibitor of MerTK, induced a less immunosuppressive phenotype of GAMs. Here, we investigate the role of MerTK inhibition on glioblastoma cells in the tumor microenvironment in vitro and in vivo. METHODS Cytotoxicity of UNC2371 in glioblastoma cells was determined by cell viability and colony formation assays. The protein expression of MerTK, AKT, and Erk were quantified by Western blotting in UNC2371-treated glioblastoma cells. A syngeneic GL261 mouse orthotopic glioblastoma model was used to evaluate the survival benefit of UNC2371 treatment. Fluorescent multiplex immunohistochemistry (IHC) was used to evaluate the expression of CD206, an anti-inflammatory marker on GAMs in murine brain tumor tissues. RESULTS UNC2371 inhibited GBM cell growth with an EC50 &lt; 100 nM in both human U251 and mouse GL261 glioma cells, but not in GAMs. UNC2371-induced cell death and decreased cell proliferation were demonstrated by colony formation assays. UNC2371 decreased protein expression of phosphorylated MerTK, AKT, and Erk, which are essential for cell survival signaling, in U251 and GL261 cells. Furthermore, UNC2371 treatment prolonged survival in the mouse orthotopic GL261 glioblastoma model, suggesting that UNC2371 induces glioma cell death. A decreased of CD206+ GAMs was found in mice glioma tissues by fluorescent multiplex IHC, consistent with our previous findings in the in vitro cell-based assays. These data suggest that in addition to alleviate immunosuppression in the glioma microenvironment, UNC2371 directly inhibits GBM cell growth in vitro and in vivo. CONCLUSION Our findings suggest that UNC2371 has a therapeutic benefit via promoting GAM polarization towards proinflammatory status in the glioblastoma microenvironment and unexpectedly, inducing tumor cell death.
Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma
Authors: Ian W. Flinn, Jason R. Westin, Jonathon B. Cohen, Luke P. Akard, Samantha Jaglowski, Jessica Sachs, Ann Ranger, Patricia Harris, Francis Payumo, Veronika Bachanova
Journal: Blood (2019)
Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor
Authors: John F. DiPersio, Jonathan Hoggatt, Steven Devine, Lukasz Biernat, Haley Howell, Veit Schmelmer, Jason R. Neale, Anthony E. Boitano, Michael P. Cooke, Kevin A. Goncalves, Glen D. Raffel, Patrick C. Falahee, Dwight M. Morrow, John C. Davis
Journal: Blood (2019)
Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Japan
Authors: Shohei Mizuno, Masamitsu Yanada, Koji Kawamura, Shingo Yano, Masayoshi Masuko, Naoyuki Uchida, Yukiyasu Ozawa, Koji Iwato, Kazuteru Ohashi, Kazuhiro Ikegame, Sung-Won Kim, Masatsugu Tanaka, Tetsuya Eto, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Akiyoshi Takami
Journal: Blood (2019)